{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:39:57Z","timestamp":1792625997507,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T00:00:00Z","timestamp":1792281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10549-026-08108-y","type":"journal-article","created":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:01:49Z","timestamp":1792346509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical management in HER2\u2009+\u2009de novo metastatic breast cancer: disease progression and survival"],"prefix":"10.1007","volume":"220","author":[{"given":"Malia","family":"Brennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara H.","family":"Javid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan R.","family":"Flanagan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Schmicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Gwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Fleuret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Palmquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,18]]},"reference":[{"issue":"3","key":"8108_CR1","doi-asserted-by":"publisher","first-page":"100114","DOI":"10.1016\/j.esmoop.2021.100114","volume":"6","author":"T Grinda","year":"2021","unstructured":"Grinda T, Antoine A, Jacot W et al (2021) Evolution of overall survival and receipt of new therapies by subtype among 20 446 metastatic breast cancer patients in the 2008\u20132017 ESME cohort. ESMO Open 6(3):100114. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100114","journal-title":"ESMO Open"},{"issue":"11","key":"8108_CR2","first-page":"CD011276","volume":"11","author":"G Tosello","year":"2025","unstructured":"Tosello G, Riera R, Torloni MR et al (2025) Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev 11(11):CD011276","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"8108_CR3","doi-asserted-by":"publisher","first-page":"5811","DOI":"10.1245\/s10434-022-11843-4","volume":"29","author":"SA Khan","year":"2022","unstructured":"Khan SA, Schuetz S, Hosseini O (2022) Primary-site local therapy for patients with de novo metastatic breast cancer: an educational review. Ann Surg Oncol 29(9):5811\u20135820. https:\/\/doi.org\/10.1245\/s10434-022-11843-4","journal-title":"Ann Surg Oncol"},{"key":"8108_CR4","unstructured":"National Comprehensive Cancer Network. Breast Cancer. Version 6 (2026) https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/breast.pdf. Accessed 29 August 2026"},{"issue":"13","key":"8108_CR5","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/S1470-2045(15)00135-7","volume":"16","author":"R Badwe","year":"2015","unstructured":"Badwe R, Hawaldar R, Nair N et al (2015) Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial. Lancet Oncol 16(13):1380\u20131388. https:\/\/doi.org\/10.1016\/S1470-2045(15)00135-7","journal-title":"Lancet Oncol"},{"issue":"9","key":"8108_CR6","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1200\/JCO.21.02006","volume":"40","author":"SA Khan","year":"2022","unstructured":"Khan SA, Zhao F, Goldstein LJ et al (2022) Early local therapy for the primary site in de novo stage IV breast cancer: Results of a randomized clinical trial (EA2108). J Clin Oncol 40(9):978\u2013987. https:\/\/doi.org\/10.1200\/JCO.21.02006","journal-title":"J Clin Oncol"},{"issue":"11","key":"8108_CR7","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1245\/s10434-018-6494-6","volume":"25","author":"A Soran","year":"2018","unstructured":"Soran A, Ozmen V, Ozbas S et al (2018) Randomized trial comparing resection of primary tumor with no surgery in stage IV breast cancer at presentation: protocol MF07-01. Ann Surg Oncol 25(11):3141\u20133149. https:\/\/doi.org\/10.1245\/s10434-018-6494-6","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"8108_CR8","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1001\/jamasurg.2015.4539","volume":"151","author":"A Thomas","year":"2016","unstructured":"Thomas A, Khan SA, Chrischilles EA, Schroeder MC (2016) Initial surgery and survival in stage IV breast cancer in the United States, 1988\u20132011. JAMA Surg 151(5):424\u2013431. https:\/\/doi.org\/10.1001\/jamasurg.2015.4539","journal-title":"JAMA Surg"},{"issue":"suppl 16","key":"8108_CR9","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1200\/JCO.2024.42.16_suppl.1590","volume":"42","author":"J Dickerson","year":"2024","unstructured":"Dickerson J, Tang H, Thompson C et al (2024) Use of surgery for de novo metastatic breast cancer (mBC). J Clin Oncol 42(suppl 16):1590. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.1590","journal-title":"J Clin Oncol"},{"issue":"8","key":"8108_CR10","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1002\/cncr.23801","volume":"113","author":"HW Hazard","year":"2008","unstructured":"Hazard HW, Gorla SR, Scholtens D, Kiel K, Gradishar WJ, Khan SA (2008) Surgical resection of the primary tumor, chest wall control, and survival in women with metastatic breast cancer. Cancer 113(8):2011\u20132019. https:\/\/doi.org\/10.1002\/cncr.23801","journal-title":"Cancer"},{"key":"8108_CR11","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1245\/s10434-020-08306-1","volume":"27","author":"R Mudgway","year":"2020","unstructured":"Mudgway R, Chavez de Paz Villanueva C, Lin AC et al (2020) The impact of primary tumor surgery on survival in HER2-positive stage IV breast cancer patients in the current era of targeted therapy. Ann Surg Oncol 27:2711\u20132720. https:\/\/doi.org\/10.1245\/s10434-020-08306-1","journal-title":"Ann Surg Oncol"},{"key":"8108_CR12","doi-asserted-by":"publisher","first-page":"1347809","DOI":"10.3389\/fonc.2024.1347809","volume":"14","author":"G Lu","year":"2024","unstructured":"Lu G, Jia L, Yang R, Liu Y, Lv Z, Cui J (2024) Primary site surgery of de novo stage IV HER2-positive breast cancer in the era of new drug treatments. Front Oncol 14:1347809. https:\/\/doi.org\/10.3389\/fonc.2024.1347809","journal-title":"Front Oncol"},{"issue":"9","key":"8108_CR13","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1245\/s10434-021-096321-8","volume":"28","author":"A Soran","year":"2021","unstructured":"Soran A, Dogan L, Isik A et al (2021) The effect of primary surgery in patients with de novo stage IV breast cancer with bone metastasis only (protocol BOMET MF14-01): a multi-center, prospective registry study. Ann Surg Oncol 28(9):5048\u20135057. https:\/\/doi.org\/10.1245\/s10434-021-096321-8","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"8108_CR14","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1038\/s41598-020-59752-6","volume":"10","author":"R Gera","year":"2020","unstructured":"Gera R, Chehade HELH, Wazir U, Tayeh S, Kasem A, Mokbel K (2020) Locoregional therapy of the primary tumour in de novo stage IV breast cancer in 216 066 patients: a meta-analysis. Sci Rep 10(1):2952. https:\/\/doi.org\/10.1038\/s41598-020-59752-6","journal-title":"Sci Rep"},{"issue":"12","key":"8108_CR15","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","volume":"23","author":"HM Kuerer","year":"2022","unstructured":"Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Exceptional Responders Clinical Trials Group (2022) Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517\u20131524","journal-title":"Lancet Oncol"},{"issue":"1","key":"8108_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41523-023-00555-w","volume":"9","author":"AC Garrido-Castro","year":"2023","unstructured":"Garrido-Castro AC, Regan MM, Niman SM, Nakhlis F, Remolano C, Rosenbluth JM, Block C, Warren LE, Bellon JR, Yeh E, Harrison BT, Troll E, Lin NU, Tolaney SM, Overmoyer B, Lynce F (2023) Clinical outcomes of de novo metastatic HER2-positive inflammatory breast cancer. NPJ Breast Cancer 9(1):50. https:\/\/doi.org\/10.1038\/s41523-023-00555-w","journal-title":"NPJ Breast Cancer"},{"issue":"5","key":"8108_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/s41416-025-03097-z","volume":"133","author":"T Shien","year":"2025","unstructured":"Shien T, Hara F, Aogi K et al (2025) Primary tumour resection plus systemic therapy versus systemic therapy alone in metastatic breast cancer (JCOG1017, PRIM-BC): a randomised clinical trial. Br J Cancer 133(5):625\u2013632. https:\/\/doi.org\/10.1038\/s41416-025-03097-z","journal-title":"Br J Cancer"},{"key":"8108_CR18","doi-asserted-by":"publisher","first-page":"102784","DOI":"10.1016\/j.ctrv.2024.102784","volume":"129","author":"W Zhou","year":"2024","unstructured":"Zhou W, Yue Y, Xiong J, Li W, Zeng X (2024) The role of locoregional surgery in de novo stage IV breast cancer: A meta-analysis of randomized controlled trials. Cancer Treat Rev 129:102784. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102784","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"8108_CR19","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1001\/jamaoncol.2025.0207","volume":"11","author":"HM Kuerer","year":"2025","unstructured":"Kuerer HM, Valero V, Smith BD et al (2025) Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol 11(5):529\u2013534. https:\/\/doi.org\/10.1001\/jamaoncol.2025.0207","journal-title":"JAMA Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08108-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08108-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-026-08108-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:06:06Z","timestamp":1792623966000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-026-08108-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,18]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["8108"],"URL":"https:\/\/doi.org\/10.1007\/s10549-026-08108-y","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,18]]},"assertion":[{"value":"17 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the University of Washington Research IRB Committee.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that the study design removed all identifiable patient factors and informed consent was not deemed necessary by IRB review.","order":2,"name":"Ethics","label":"Consent to participate and publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"7"}}